Skip to main content
. 2022 Apr 25;13:834113. doi: 10.3389/fphar.2022.834113

FIGURE 2.

FIGURE 2

Subgroup analyses of best objective response rate (BOR) of patients with diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T cells (CAR-Ts) according to (A) study design, (B) the costimulatory domain, and (C) type of chimeric antigen receptor T cells (CAR-T).